6/30/23, 2:19 AM TRANSFORM-HF Pathway Feedback Search Clinical Topics Home Studies TRANSFORM HF TRANSFORM HF Disease Heart failure Trial question Is torsemide superior to furosemide in patients hospitalized with HF? Study design Multi-center Open label RCT Population Characteristics of study participants 37.0% female N = 2859 63.0% male 2859 patients (1058 female, 1801 male) Inclusion criteria: in-hospital patients with new or worsening HF Key exclusion criteria: RRT; heart transplant; implant anticipated in < 3 months; life expectancy < 12 months; known hypersensitivity to study drugs Interventions N=1431 torsemide (oral dose left to the treating physician) N=1428 furosemide (oral dose between 2:1 and 4:1 of torsemide's) Primary outcome Death from all causes 26.2 % 26.1 26.2 https://web.pathway.md/studies/recz1VZ1NGjr1OXy9 1/2 6/30/23, 2:19 AM TRANSFORM-HF Pathway 6 6 19.6 % 13.1 % 6.5 % No significant difference 0.0 % Torsemide Furosemide No significant difference in death from all causes (26.1% vs. 26.2%; HR 1.02, 95% CI 0.89 to 1.18) Secondary outcomes No significant difference in death from all causes or hospitalization at 12 months (47.3% vs. 49.3%; HR 0.92, 95% CI 0.83 to 1.02) No significant difference in total hospitalizations at 12 months (37.5% vs. 40.4%; RR 0.94, 95% CI 0.84 to 1.07) Conclusion In in-hospital patients with new or worsening HF, torsemide was not superior to furosemide with respect to death from all causes. Reference Frederik H Verbrugge, Venu Menon. Torsemide comparison with furosemide for management of heart failure (TRANSFORM-HF) trial. Eur Heart J Acute Cardiovasc Care. 2022 Dec 27;11(12):931- 932. Open reference URL https://web.pathway.md/studies/recz1VZ1NGjr1OXy9 2/2